San Francisco-based molecular diagnostics startup MLC Dx recently disclosed several company executives in an SEC filing.
Thomas Willis is the company’s president and CEO. Prior to that, he worked at Affymetrix, following the firm’s acquisition of ParAllele BioScience, a company he co-founded and where he served as CEO and later as CSO.
Malek Faham is the firm’s CSO. Previously, he was vice president of oncology technology research at Affymetrix, and before that, director of research at ParAllele, which he also co-founded.
Lawrence Tabak has been appointed as principal deputy director of the National Institutes of Health. He succeeds Raynard Kington, who is leaving the NIH to become president of Grinnell College in Iowa.
Tabak has served as director of the National Institute of Dental and Craniofacial Research since 2000. He also served as acting NIH deputy director in 2009 and, most recently, as acting director of the Division of Program Coordination, Planning, and Strategic Initiatives. Previously, he was a professor of dentistry, biochemistry, and biophysics at the School of Medicine and Dentistry at the University of Rochester. He holds a DDS from Columbia University, a PhD and a certificate of proficiency in endodontics from the University of Buffalo, and an undergraduate degree from City College of the City University of New York.